



NEWS RELEASE

Media Contact:

Elizabeth Somers
Director, Business Development
Fujirebio Diagnostics, Inc.
somerse@fujirebiodiagnostics.com

FUJIREBIO DIAGNOSTICS SIGNS AGREEMENT WITH NORTH AMERICAN DISTRIBUTOR

Malvern, Pa., December 18, 1998 - Fujirebio Diagnostics, Inc. (formerly Centocor Diagnostics of Pennsylvania, Inc.) today announced that it has signed an agreement with Polymedco, Inc. (Cortland Manor, N.Y.) for North American distribution of the company's line of cancer diagnostics products. This agreement takes effect 12/21/98. Polymedco will distribute the company's Tumor Marker Assays CA125AII, CA19-9, CA15-3, CA72-4, and Cyfra21-1 containing monoclonal antibodies developed by Centocor, Inc., as well as the Truquant BR and GI Assays containing antibodies developed by Biomira, Inc. These products utilize monoclonal antibodies to aid in monitoring of tumor-associated antigens.

"We are extremely pleased about this partnership with Polymedco, a leading distributor in the industry, because it will enable one distributor to carry the complete line of the company's tumor markers" said Aris Petropoulos, chief operating officer, Fujirebio Diagnostics. "This should result in improved services to the clinical community." The company's tumor marker assays containing monoclonal antibodies developed by Centocor, Inc. are recognized worldwide as the gold-standard in diagnostic cancer assays. The product line is supported with more than 2,000 peer-reviewed articles which give it an extensive history and database of clinical studies, research and clinical use.

Polymedco is a leading distributor of diagnostic products in the United States and currently has an extensive customer base utilizing the Truquant tumor marker assays. The agreement allows Polymedco to add additional tumor marker assays to its portfolio and expand its assay menu for clinicians.

Fujirebio Inc. of Tokyo is a leading diagnostic company in Japan and recently acquired the diagnostic business from Centocor, Inc. Fujirebio continues to produce the tumor marker assays in the existing Centocor production facility in Malvern utilizing the same personnel, procedures and cell lines. Fisher will continue United States distribution of the company's tumor marker diagnostic products containing monoclonal antibodies developed by Centocor, Inc.